Kennedy eases restrictions on six unproven peptides despite FDA safety concerns
US Health Secretary Robert F. Kennedy has directed the government to stop enforcing restrictions that prevented specialty pharmacies from making and selling six unproven peptides. The move bypasses the FDA’s 2023 action, despite agency scientists’ concerns that there is not enough evidence to establish whether the drugs work or are safe.
The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Kennedy’s policy says wider pharmacy access could be safer than patients obtaining products through grey or black markets, but the limited human research means potential harms and benefits remain unclear. The article also notes that several members newly appointed to an FDA advisory panel that backed the peptides had ties to peptide businesses.
In short
- Kennedy has eased enforcement for pharmacies selling six unproven peptides.
- FDA scientists say evidence of safety and effectiveness is insufficient.
- Several panel members who supported the peptides had industry ties.
Read the full article at the source →
Originally published by Ars Technica as “Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA”.